It was a profitable quarter for San Francisco-based McKesson.
The company's profit for Q1 2016, ended June 30, 2015, totaled $576 million, a 43 percent increase from the $403 million posted for the same time period last year.
Additionally, McKesson posted $47.5 billion in revenue for the quarter, up 9 percent from $43.5 billion a year ago.
According to a Wall Street Journal report, McKesson has benefited from the sale of two hepatitis C drugs, Gilead Sciences' Sovaldi and Harvoni, which have been two of the most successful drug launches in history.
More articles on health IT:
Epic, Cerner, McKesson among highest IT revenue last year; athenahealth launches free messaging platform; Epic snags 2 new customers — 5 health IT key notes
How to create a culture of innovation: 6 lessons from Edward Marx
'Think, build and run': 4 IT leaders discuss the future of the industry